Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products.[4] It is a major producer of branded oncology medicines[5] cardiology, diabetology and other pharma specialty drugs at affordable prices.[6][7][8][9]
Natco Pharma was founded in 1981 by V C Nannapaneni. In 1983, operations commenced at manufacturing facility at
In 2008, Natco Pharma filed its first paragraph IV filing in the US with the USFDA,[10] In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[11] In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[10]
In 2016, Natco Pharma launched the first Tamiflu capsule in the US market.[12] In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide in the United States.[13] In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.[14]
In 2025, Natco Pharma completed the acquisition of a 35.75% stake in Adcock Ingram, a South African pharmaceutical company, for approximately US$226 million. The acquisition resulted in the delisting of Adcock Ingram from the Johannesburg Stock Exchange.[15][16][17]
